NCT05506891

Efficacy and Safety of Astragalus for Non-motor Symptoms of α-Synucleinopathy

Efficacy and Safety of Astragalus for Non-Motor Symptoms of α-Synucleinopathy：an Open-Label Self-Controlled Before-and-After Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Fujian Medical University Union Hospital · Academic / Other
• Sex: All
• Age: 30 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

α-Synucleinopathy is a cluster of neurodegenerative disease with motor and non-motor symptom. However, there is still a lack of research on the treatment for non-motor symptoms of α-synucleinopathy, especially autonomic dysfunctions such as orthostatic hypotension. Efficacy and safety of astragalus for non-motor symptoms of α-synucleinopathy will be assessed by an open-label self-controlled before-and-after study.

Conditions

• Parkinsonism

Interventions

Type	Name	Description
BEHAVIORAL	Physical therapy group	Limit water and sodium intake. Raise the head of the bed. Standardized amount of exercise. Low temperature diet and small meals. Avoid alcohol, coffee and dehydration. The treatment lasted for 3 months.
DRUG	Astragalus	After a 2-week washout period, astragalus granules 15g, drunk with warm water, once a day, will be taken for 3 months.

Timeline

• Start date: 2023-10-01
• Primary completion: 2024-07-01
• Completion: 2024-07-01
• First posted: 2022-08-18
• Last updated: 2023-09-13

Locations

1 site across 1 country: China